Kiniksa Pharmaceuticals International, plc $KNSA Shares Newly Purchased by Sowell Financial Services LLC

Key Points

• Sowell Financial Services purchased 40,735 Kiniksa shares worth approximately $3.04 million, while institutional investors collectively own 53.95% of the company.
• Analyst sentiment remains positive, with seven Buy ratings and two Holds; the consensus rating is Moderate Buy and the average price target is $100.57.
• Kiniksa exceeded quarterly expectations, reporting $0.56 in EPS versus the $0.37 consensus and revenue of $285.97 million versus estimates of $260.66 million.

Sowell Financial Services LLC bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,735 shares of the company's stock, valued at approximately $3,039,000. Sowell Financial Services LLC owned about 0.05% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of KNSA. Headlands Technologies LLC purchased a new stake in Kiniksa Pharmaceuticals International during the second quarter worth about $1,161,000. OMERS ADMINISTRATION Corp bought a new stake in Kiniksa Pharmaceuticals International in the first quarter worth about $631,000. Handelsbanken Fonder AB bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth about $1,343,000. The Manufacturers Life Insurance Company boosted its stake in Kiniksa Pharmaceuticals International by 56.7% in the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company's stock valued at $3,050,000 after acquiring an additional 22,917 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company's stock valued at $23,197,000 after acquiring an additional 327,595 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 51.98% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on KNSA. Canaccord Genuity Group raised their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Citigroup upped their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a report on Wednesday. Finally, Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an "outperform" rating in a report on Wednesday. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $100.57.

Kiniksa Pharmaceuticals International Trading Down 5.5%

KNSA stock opened at $92.24 on Friday. The company's 50 day moving average is $79.15 and its 200 day moving average is $60.03. The stock has a market cap of $7.20 billion, a price-to-earnings ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 1-year low of $36.56 and a 1-year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.